한스바이오메드
Financials
Valuation Metrics
한스바이오메드's Market Cap is ₩2597B. At end of 2025 it was ₩3936B. Ranked #726 of 2,421 in KR market (top 30%), #314 of 1,640 on KOSDAQ (top 19%), #77 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 33%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 259.70B KRW | KR#726/2,421 Sec#77/231 |
| Revenue | 89.78B KRW | KR#1,478/2,421 Sec#91/231 |
| Net Income | -32.08B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 126.41B KRW | KR#1,613/2,421 Sec#126/231 |
| Net Assets | 33.89B KRW | KR#2,137/2,421 Sec#187/231 |
| Employees | 247 | KR#936/2,421 Sec#80/231 |
| Value | ||
| P/B | 7.66x | KR#2,327/2,421 Sec#205/231 |
| P/S | 2.89x | KR#1,969/2,421 Sec#121/231 |
| FCF Yield | -0.53% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -94.65% | KR#2,337/2,421 Sec#214/231 |
| ROA | -25.37% | KR#2,283/2,421 Sec#190/231 |
| Op. Margin | -28.84% | KR#2,174/2,421 Sec#153/231 |
| Revenue Growth | 10.65% | KR#869/2,421 Sec#82/231 |
| Financial Health | ||
| Debt Ratio | 273.03% | KR#2,233/2,421 Sec#223/231 |
| Total Debt | 76.60B KRW | KR#827/2,421 Sec#52/231 |
| FCF | -1.38B KRW | KR#1,300/2,421 Sec#100/231 |
| Cash | 8.15B KRW | KR#1,804/2,421 Sec#161/231 |
| Current Ratio | 0.69x | KR#2,036/2,421 Sec#194/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | 13.81% | KR#515/2,421 Sec#32/231 |
| 1M Return | -4.46% | KR#1,746/2,421 Sec#137/231 |
| From 52W High | -68.49% | KR#2,155/2,421 Sec#184/231 |
| 1Y MDD | -69.46% | KR#1,969/2,421 Sec#169/231 |
| Trading | ||
| Volume | 79,672 shares | KR#895/2,421 Sec#92/231 |
| Trading Value | 1.45B KRW | KR#630/2,421 Sec#62/231 |
| Foreign Own. | 6.28% | KR#702/2,421 Sec#61/231 |
| Per Share | ||
| EPS | -2,249 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,376 KRW | KR#1,987/2,421 Sec#161/231 |
Company Info
Established in 1999, this company manufactures and sells human implantable skin, bone graft materials, and medical devices, having been listed on KOSDAQ in 2009. It is the first bio-company in Asia to successfully commercialize human skin, bone, and silicone implant products, receiving South Korea's first human tissue bank establishment license from the Ministry of Food and Drug Safety. The company is expanding its global business through overseas subsidiaries in the United States, Thailand, and the United Kingdom, and continuously increases R&D investments in new medical technology fields such as tissue engineering and vascular hemostatic devices. HansBiomed was established in 1999 and is headquartered in Songpa-gu, Seoul Metropolitan City.